Trials / Completed
CompletedNCT00740532
Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients
Observational Study Assessing Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 11 (actual)
- Sponsor
- Istituto Clinico Humanitas · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Aim of the study is to assess the impact on response to Herceptin-based therapy in patients with advanced breast cancer. Tumor specimens from primary breast cancer will be analized for several biological factors potentially involved in Herceptin sensitivity. Tests that will be performed include: FISH analyses of EGFR, HER-2, HER-3, C-MYC, PTEN, MET, IGFR-1. Immunofluorecence of P95HER2. Mutation analyses of EGFR, HER-2, MET, C-MYC, PTEN, KRAS, PIK3CA, IGFR-1. Immunohistochemistry of the same biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Gene mutation analyses and FISH | FISH and mutation analyses of multiple genes |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2008-03-01
- Completion
- 2010-08-01
- First posted
- 2008-08-25
- Last updated
- 2010-09-02
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT00740532. Inclusion in this directory is not an endorsement.